A Registry for People With T-cell Lymphoma

Memorial Sloan Kettering Cancer Center (MSK)

Status: Enrolling

Conditions: Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder); Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Aggressive NK-cell Leukemia; Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form; Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood; Intestinal T-Cell Lymphoma, Not Otherwise Specified; Hydroa Vacciniforme-Like Lymphoproliferative Disorder; Anaplastic Large Cell Lymphoma, ALK-negative; T-cell Lymphoma; NK-Cell Lymphoma; Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Primary Cutaneous T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-Positive; Mycosis Fungoides; T-cell Prolymphocytic Leukemia; Chronic Lymphoproliferative Disorder of NK Cells; Breast Implant-Associated Anaplastic Large Cell Lymphoma; T-cell Large Granular Lymphocytic Leukemia; Primary Cutaneous Anaplastic Large Cell Lymphoma; Subcutaneous Panniculitis-Like T-Cell Lymphoma; Follicular T-Cell Lymphoma; Enteropathy-associated T-cell Lymphoma; Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma; Sezary Syndrome; Hepatosplenic T-cell Lymphoma; Extranodal NK/T-cell Lymphoma, Nasal Type; Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract; Adult T-cell Leukemia/Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Treatments: Other: Optional Blood Sample and Nail Sample

Study type: Observational

Funder types: Other

Identifiers

NCT05978141

23-190

Details and patient eligibility

About

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent

• Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.

• Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

  • T-cell prolymphocytic leukemia
  • T-cell large granular lymphocytic leukemia
  • Chronic lymphoproliferative disorder of NK cells
  • Aggressive NK-cell leukemia
  • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • Chronic active EBV infection of T- and NK-cell type, systemic form
  • Hydroa vacciniforme-like lymphoproliferative disorder
  • Adult T-cell leukemia/lymphoma
  • Extranodal NK/T-cell lymphoma, nasal type
  • Enteropathy-associated T-cell lymphoma
  • Monomorphic epitheliotropic intestinal T-cell lymphoma
  • Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • Sézary syndrome
  • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • Primary cutaneous Gamma-Delta T-cell lymphoma
  • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • Peripheral T-cell lymphoma, not otherwise specified
  • Angioimmunoblastic T-cell lymphoma
  • Follicular T-cell lymphoma
  • Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic large cell lymphoma, ALK-positive
  • Anaplastic large cell lymphoma, ALK-negative
  • Breast-implant associated anaplastic large cell lymphoma.

• NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion criteria

• Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
• Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Trial design

1,000 participants in 1 patient group

Participants with T-Cell Lymphoma

Description:

Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma

Treatment:

Other: Optional Blood Sample and Nail Sample